Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension

Massimo Volpe; Alejandro De La Sierra; Bettina Ammentorp; Petra Laeis

doi:10.1007/s12325-014-0117-9

Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension

Massimo Volpe, Alejandro De La Sierra, Bettina Ammentorp, Petra Laeis

www.neuromed.it

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: To reduce cardiovascular risk associated with hypertension, the majority of patients require at least two drugs to control their blood pressure (BP), and many require three or more. Methods: An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension. After 8 weeks of single-blind OLM/AML/HCTZ 20/5/12.5 mg treatment, patients at BP goal [seated systolic/diastolic BP (SeSBP/SeDBP)

Original language	English
Pages (from-to)	561-574
Number of pages	14
Journal	Advances in Therapy
Volume	31
Issue number	5
DOIs	https://doi.org/10.1007/s12325-014-0117-9
Publication status	Published - 2014

Keywords

Cardiology
Hypertension
Olmesartan/amlodipine/hydrochlorothiazide
Open-label
Seated diastolic blood pressure
Seated systolic blood pressure
Triple combination

ASJC Scopus subject areas

Medicine(all)
Pharmacology (medical)

Access to Document

10.1007/s12325-014-0117-9

Cite this

@article{4f8d4b006e6d40fba68b62f590ba1445,

title = "Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension",

abstract = "Introduction: To reduce cardiovascular risk associated with hypertension, the majority of patients require at least two drugs to control their blood pressure (BP), and many require three or more. Methods: An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension. After 8 weeks of single-blind OLM/AML/HCTZ 20/5/12.5 mg treatment, patients at BP goal [seated systolic/diastolic BP (SeSBP/SeDBP) ",

keywords = "Cardiology, Hypertension, Olmesartan/amlodipine/hydrochlorothiazide, Open-label, Seated diastolic blood pressure, Seated systolic blood pressure, Triple combination",

author = "Massimo Volpe and {De La Sierra}, Alejandro and Bettina Ammentorp and Petra Laeis",

year = "2014",

doi = "10.1007/s12325-014-0117-9",

language = "English",

volume = "31",

pages = "561--574",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Springer Healthcare",

number = "5",

}

TY - JOUR

T1 - Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension

AU - Volpe, Massimo

AU - De La Sierra, Alejandro

AU - Ammentorp, Bettina

AU - Laeis, Petra

PY - 2014

Y1 - 2014

N2 - Introduction: To reduce cardiovascular risk associated with hypertension, the majority of patients require at least two drugs to control their blood pressure (BP), and many require three or more. Methods: An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension. After 8 weeks of single-blind OLM/AML/HCTZ 20/5/12.5 mg treatment, patients at BP goal [seated systolic/diastolic BP (SeSBP/SeDBP)

AB - Introduction: To reduce cardiovascular risk associated with hypertension, the majority of patients require at least two drugs to control their blood pressure (BP), and many require three or more. Methods: An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension. After 8 weeks of single-blind OLM/AML/HCTZ 20/5/12.5 mg treatment, patients at BP goal [seated systolic/diastolic BP (SeSBP/SeDBP)

KW - Cardiology

KW - Hypertension

KW - Olmesartan/amlodipine/hydrochlorothiazide

KW - Open-label

KW - Seated diastolic blood pressure

KW - Seated systolic blood pressure

KW - Triple combination

UR - http://www.scopus.com/inward/record.url?scp=84903773938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903773938&partnerID=8YFLogxK

U2 - 10.1007/s12325-014-0117-9

DO - 10.1007/s12325-014-0117-9

M3 - Article

C2 - 24760656

AN - SCOPUS:84903773938

VL - 31

SP - 561

EP - 574

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 5

ER -

Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this